Welcome to our dedicated page for Hemogenyx Pharma news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharma stock.
Hemogenyx Pharma PLC (HOPHF), associated with Hemogenyx Pharmaceuticals plc (LSE: HEMO), generates news primarily around its clinical development, financing, and strategic collaboration activities in biotechnology. The company describes itself as a clinical stage biopharmaceutical group developing new medicines and treatments for blood and autoimmune diseases, with a particular focus on its HG-CT-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML).
News updates frequently cover milestones in the Phase I clinical trial of HG-CT-1, including first-in-human dosing, safety evaluations, early signs of efficacy, and decisions by the independent Data Safety Monitoring Board on dose escalation. Additional coverage includes regulatory developments such as FDA interactions, Institutional Review Board approvals for pediatric enrollment, and broader trial design updates for both adult and pediatric patients.
Hemogenyx Pharmaceuticals also issues announcements on operational and strategic initiatives, such as its manufacturing partnership with Made Scientific to support HG-CT-1 production and its letter of intent with Cellin Technologies in Estonia to explore commercialization under the hospital exemption pathway. Capital markets news includes publication of a prospectus, share issuances arising from warrant exercises and restricted stock units, and updates on admission of new shares to the Official List and to trading on the London Stock Exchange.
Visitors to this news page can review a stream of company disclosures that document clinical progress, financing activities, manufacturing arrangements, and potential early revenue pathways. For investors and observers interested in CAR-T therapies, hematology-oncology, and early-stage biopharmaceutical development, Hemogenyx-related news provides insight into how the company is advancing its lead program and supporting infrastructure over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Hemogenyx Pharmaceuticals has announced the successful completion of analytical tests for its HEMO-CAR-T production across three Process Qualification (PQ) runs. These PQ runs, conducted in cGMP compliant facilities, are crucial for ensuring the quality of the manufactured cells, focusing on attributes like viability, potency, and sterility. This achievement fulfills the last manufacturing requirement for submitting an Investigational New Drug (IND) application to the FDA, which is currently being prepared. The IND is necessary to initiate Phase I clinical trials for HEMO-CAR-T, marking a significant step forward in the Company's development of new therapies for blood diseases.
Hemogenyx Pharmaceuticals announced total voting rights as of February 28, 2023, confirming the issuance of 1,141,999,321 ordinary shares with a nominal value of 1 pence each. The company holds no treasury shares, resulting in the same number of voting rights available to shareholders. This figure is crucial for shareholders to determine their reporting obligations concerning changes in their shareholdings under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Hemogenyx Pharmaceuticals has successfully raised £4,056,250 through the issuance of 162,250,000 new ordinary shares at 2.5 pence per share. This fundraising effort will support the advancement of their HEMO-CAR-T product candidate into clinical trials and the development of their Chimeric Bait Receptor (CBR) platform. The shares are expected to be admitted for trading on the London Stock Exchange around February 2, 2023, increasing the total issued capital to 1,141,999,321 shares. CEO Dr. Vladislav Sandler highlighted the importance of moving forward with their key products to combat viral infections.
Hemogenyx Pharmaceuticals plc has successfully completed its third Process Qualification run for the manufacturing of HEMO-CAR-T cells in cGMP compliant facilities. This achievement is crucial for the submission of an Investigational New Drug (IND) application to the FDA, required for initiating Phase I clinical trials. The company will conduct analytical release tests to ensure the quality of these cells, which will also be tested by a third party before the data is compiled for the IND submission.